Potential Role of Magrolimab in the Treatment of Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) : Episode 2

The Progression of Myelodysplastic Syndrome to Acute Myeloid Leukemia (AML)

September 29, 2022

By Hetty E. Carraway, MD
Eytan M. Stein, MD

Video

Hetty Carraway, MD, describes how MDS differs from acute myeloid leukemia (AML), and the percentage of patients who progress to AML from MDS.

EP: 1.An Overview of Myelodysplastic Syndrome (MDS)

Now Viewing

EP: 2.The Progression of Myelodysplastic Syndrome to Acute Myeloid Leukemia (AML)

EP: 3.Risk Stratification for Patients with Myelodysplastic Syndrome

EP: 4.Treatment Goals for Patients with Myelodysplastic Syndrome

EP: 5.Currently Available Treatment Options for Patients with Higher-Risk Myelodysplastic Syndrome

EP: 6.Factors for Consideration when Choosing an Appropriate Treatment for Higher-Risk Myelodysplastic Syndrome

EP: 7.The Role of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome

EP: 8.The Role of Hypomethylating Agents (HMAs) in Higher-Risk Myelodysplastic Syndrome Treatment

EP: 9.Magrolimab plus Azacitidine for Myelodysplastic Syndrome

EP: 10.Potential Shift in the Treatment Paradigm of Higher-Risk MDS with Magrolimab

EP: 11.Treating Patients with Myelodysplastic Syndrome and IDH or TP53 Mutations

EP: 12.Unmet Needs for Patients with Higher-Risk Myelodysplastic Syndrome

EP: 13.ENHANCE-2 Trial of Magrolimab plus Azacitidine in AML

EP: 14.ENHANCE-3 Trial of Magrolimab in Combination with Venetoclax and Azacitidine in AML

Related Content

FDA Approves Revumenib in KMT2A-Rearranged Acute Leukemia

Jordyn Sava

November 15th 2024

Article

Revumenib is now an FDA-approved treatment for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute leukemia.

Revumenib for NPM1-Mutant AML Succeeds in Pivotal Trial

Jordyn Sava

November 12th 2024

Article

In the phase 2 AUGMENT-101 trial, revumenib met its primary end point by achieving a complete remission or complete remission with partial blood count recovery in relapsed/refractory NPM1-mutant acute myeloid leukemia.

$FDA Greenlights Obe-cel in Relapsed/Refractory B-ALL$

FDA Greenlights Obe-cel in Relapsed/Refractory B-ALL

Jordyn Sava

November 8th 2024

Article

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

Uproleselan With Chemo Fails to Improve EFS in Older Patients With AML

Jordyn Sava

November 2nd 2024

Article

A phase 2/3 study investigating uproleselan with standard 7+3 chemotherapy in newly diagnosed, older patients with acute myeloid leukemia did not achieve the primary end point of improved event-free survival.

FDA Expands Approval for Jylamvo Oral Methotrexate Solution in ALL

Sabrina Serani

October 29th 2024

Article

The indication for Jylamvo now includes pediatric patients with acute lymphoblastic leukemia.

$FDA Fast Tracks HC-7366 in Relapsed/Refractory Acute Myeloid Leukemia$